Linked Life Data

8876780

Source:http://linkedlifedata.com/resource/pubmed/id/8876780

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1997-1-16
pubmed:abstractText
Primary prevention trials for Alzheimer disease (AD) should be considered because of the substantial cost of caring for AD patients. Current clues to possible treatments include the potential use of antioxidants, estrogens, anti-inflammatory drugs, drugs designed to alter apolipoprotein E4 status, and compounds altering amyloid metabolism. Because of the expense of primary prevention trials, resources should be devoted to developing epidemiological clues for environmental loss in vivo and searching for additional epidemiological clues for environmental factors that may protect individuals from AD. A primary prevention trial would involve the recruitment of 4,000-5,000 subjects followed for 3-5 years at a cost of approximately $20 million. Alternatively, a primary prevention trial could be performed as an "add on" study to an existing clinical trial of a compound of interest currently being tested in an elderly population at substantially less cost.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
0893-0341
pubmed:author
pubmed:issnType
Print
pubmed:volume
10 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6-8
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Potential prevention strategies for Alzheimer disease.
pubmed:affiliation
Department of Neurosciences, University of California, San Diego, La Jolla 92093-0624, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.